Mutational spectrum and prognosis in NRAS-mutated acute myeloid leukemia.

Scientific Reports
Shujuan WangYanfang Liu

Abstract

The mutational spectrum and prognostic factors of NRAS-mutated (NRASmut) acute myeloid leukemia (AML) are largely unknown. We performed next-generation sequencing (NGS) in 1,149 cases of de novo AML and discovered 152 NRASmut AML (13%). Of the 152 NRASmut AML, 89% had at least one companion mutated gene. DNA methylation-related genes confer up to 62% incidence. TET2 had the highest mutation frequency (51%), followed by ASXL1 (17%), NPM1 (14%), CEBPA (13%), DNMT3A (13%), FLT3-ITD (11%), KIT (11%), IDH2 (9%), RUNX1 (8%), U2AF1 (7%) and SF3B1(5%). Multivariate analysis suggested that age ≥ 60 years and mutations in U2AF1 were independent factors related to failure to achieve complete remission after induction therapy. Age ≥ 60 years, non-M3 types and U2AF1 mutations were independent prognostic factors for poor overall survival. Age ≥ 60 years, non-M3 types and higher risk group were independent prognostic factors for poor event-free survival (EFS) while allogenic hematopoietic stem cell transplantation was an independent prognostic factor for good EFS. Our study provided new insights into the mutational spectrum and prognostic factors of NRASmut AML.

References

Jan 26, 2006·Blood·Ulrike BacherSusanne Schnittger
Apr 17, 2014·Annals of Hematology·Christoph W M ReuterMichael A Morgan
Nov 22, 2014·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Robert S OhgamiDaniel A Arber
Sep 17, 2015·The New England Journal of Medicine·Hartmut DöhnerClara D Bloomfield
Jun 9, 2016·The New England Journal of Medicine·Elli PapaemmanuilPeter J Campbell
Jun 12, 2016·Blood·Klaus H MetzelerUNKNOWN AMLCG Study Group
Aug 11, 2016·Drug Discovery Today·Candice Y Wilson, Peter Tolias
Mar 16, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lars BullingerHartmut Döhner
Apr 12, 2017·Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·UNKNOWN Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association
Aug 29, 2018·Journal of Medicinal Chemistry·Hanna ChoTaebo Sim
Sep 9, 2018·Clinica Chimica Acta; International Journal of Clinical Chemistry·Xin LiuXi-Long Zhao

❮ Previous
Next ❯

Software Mentioned

SPSS
Graphpad

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Cardiovascular Disease & TET2

Cardiovascular diseases are the number one cause of deaths globally. Tet methylcytosine dioxygenase 2 (TET2)-mediated hematopoiesis has been implicated in accelerating heart failure. Here is the latest research on cardiovascular diseases and TET2.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.